Supply Chain Intelligence

Bicycle Therapeutics plc Supply Chain

BCYC supply chain intelligence for Bicycle Therapeutics plc: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

BCYC ·Last updated 2026-07-29 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

3Suppliers
5Customers
3Debt Items
20Related Chains

Bicycle Therapeutics plc Suppliers

TickerNameConfidenceEvidence
CONTRACT-MANUFACTURING-ORGANIZATIONS CONTRACT-MANUFACTURING-ORGANIZATIONS 90% The Company has entered into various agreements with contract manufacturing organizations to provide clinical trial materials
CONTRACT-RESEARCH-ORGANIZATIONS CONTRACT-RESEARCH-ORGANIZATIONS 90% The Company has entered into various agreements with contract research organizations to provide clinical trial services
VENDORS VENDORS 90% The Company has entered into various agreements with vendors for preclinical research studies, synthetic chemistry and other services for operating purposes

Bicycle Therapeutics plc Customers

TickerNameConfidenceEvidence
LLY Eli Lilly and Company 72% dministered, the radiopharmaceuticals are designed to target tumor antigens that are unique to, or preferentially expressed on, cancer cells throughout the body. We believe the advantages of Bicycle …
LLY Eli Lilly and Company 72% Reciprocal relationship from LLY graph: Reciprocal relationship from BCYC graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BCYC graph: Reciprocal relationship from LLY grap…
COMPANY-CORBUS-PHARMACEUTICAL-HOLDINGS-INC COMPANY-CORBUS-PHARMACEUTICAL-HOLDINGS-INC 62% dministered, the radiopharmaceuticals are designed to target tumor antigens that are unique to, or preferentially expressed on, cancer cells throughout the body. We believe the advantages of Bicycle …
COORDINATION-GROUP COORDINATION-GROUP 62% dministered, the radiopharmaceuticals are designed to target tumor antigens that are unique to, or preferentially expressed on, cancer cells throughout the body. We believe the advantages of Bicycle …
MABWELL-THERAPEUTICS-INC MABWELL-THERAPEUTICS-INC 62% dministered, the radiopharmaceuticals are designed to target tumor antigens that are unique to, or preferentially expressed on, cancer cells throughout the body. We believe the advantages of Bicycle …

Bicycle Therapeutics plc Debt Obligations

InstrumentDescriptionConfidenceEvidence
BCYC-DEBT Debt stack $16.9M 90% Market cache reports total debt of $16.9M.
BCYC-DEBT-8114 Warrants outstanding: 92885 90% xbrl warrant detail from xbrl 2020-12-31.
BCYC-DEBT-8115 Xbrl Convertible 90% xbrl convertible detail from xbrl 2019-12-31.

Bicycle Therapeutics plc Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Bicycle Therapeutics plc.

Bicycle Therapeutics plc Ownership

HolderNameConfidenceEvidence
BCYC-OWNER-BAKER-BROS-ADVISORS-LP BAKER BROS. ADVISORS LP 90% 13F overlay lists BAKER BROS. ADVISORS LP as top holder; 100 tracked holders.

Bicycle Therapeutics plc Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
VNDA Vanda Pharmaceuticals Inc. 100.00 2
SDGR Schrödinger, Inc. 100.00 2
CPRX Catalyst Pharmaceuticals, Inc. 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
ALT Altimmune, Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
SVRA Savara Inc. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
AKTS Aktis Oncology, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
EDSA Edesa Biotech, Inc. 100.00 2
DYN Dyne Therapeutics, Inc. 100.00 2
CAPR Capricor Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
FHTX Foghorn Therapeutics Inc. 100.00 2
NVO Novo Nordisk A/S 100.00 2
IRON Disc Medicine, Inc. 100.00 2
ALEC Alector, Inc. 100.00 2
View BCYC supply chain intel →

Explore the full interactive supply chain map for Bicycle Therapeutics plc.

Open BCYC supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map